通常データ分析・統計
Biosimilar Market Size, Share, Trends, Key Drivers, Demand and Opportunity Analysisプロンプト
- The global biosimilar market size was valued at USD 64.93 billion in 2024 and is expected to reach USD 598.55 billion by 2032, at a CAGR of 32.00% during the forecast period
- The market expansion is primarily driven by the growing number of patent expiries of blockbuster biologics and the rising prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes, which are fueling demand for cost-effective alternatives
- In addition, favorable regulatory frameworks, increasing investments from pharmaceutical companies, and greater healthcare provider acceptance are accelerating the development and adoption of biosimilars worldwide. These trends are significantly contributing to the strong growth trajectory of the biosimilar industry
プロンプト本文
"Global Executive Summary Biosimilar Market: Size, Share, and Forecast
The global biosimilar market size was valued at USD 64.93 billion in 2024 and is expected to reach USD 598.55 billion by 2032, at a CAGR of 32.00% during the forecast period
The market expansion is primarily driven by the growing number of patent expiries of blockbuster biologics and the rising prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes, which are fueling demand for cost-effective alternatives
In addition, favorable regulatory frameworks, increasing investments from pharmaceutical companies, and greater healthcare provider acceptance are accelerating the development and adoption of biosimilars worldwide. These trends are significantly contributing to the strong growth trajectory of the biosimilar industry
The Biosimilar Market analysis report focuses on leading global industry players, providing information such as company profiles, product pictures and specifications, capacity, production, price, cost, revenue, and contact information. Geographically, this report is categorized into various main regions, including sales, proceeds, market share and expansion rate (percent) in the following areas: North America, Asia-Pacific, South America, Europe, Asia-Pacific, The Middle East and Africa. What is more, the feasibility of new investment projects is assessed and overall research conclusions are offered. Analysis of profiles of manufacturers or commanding players of the global market is performed based on sales area, key products, gross margin, revenue, price, and production.
Biosimilar Market Analysis report analyzes the changing trends in the industry. The industry development trends and marketing channels are also analyzed. In this market document, development policies and plans are discussed, and manufacturing processes and cost structures are also analyzed. The report offers a detailed analysis of Biosimilar Market industry with growth & significant CAGR during the forecast period by top manufacturer’s analysis, region, types, and market segment by applications. The market research study of this report is conducted to understand the current landscape of the global market.
Stay ahead with crucial trends and expert analysis in the latest Biosimilar Market report. Download now:
https://www.databridgemarketresearch.com/reports/global-biosimilar-market
Biosimilar Industry Overview
Segments
- By Product Type
- Recombinant Non-Glycosylated Proteins
- Recombinant Glycosylated Proteins
- Recombinant Peptides
- By Indication
- Oncology
- Chronic Disease
- Autoimmune Disease
- Infectious Disease
- By Manufacturing
- In-House Manufacturing
- Contract Manufacturing
The global biosimilar market is segmented based on product type, indication, and manufacturing. In terms of product type, the market is categorized into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins segment is expected to witness significant growth due to the increasing prevalence of chronic diseases and the demand for cost-effective treatment options. By indication, the market is segmented into oncology, chronic disease, autoimmune disease, and infectious disease. The oncology segment is anticipated to dominate the market as biosimilars offer a more affordable alternative to expensive biologics for cancer treatment. When it comes to manufacturing, the market is divided into in-house manufacturing and contract manufacturing. Contract manufacturing is gaining traction as it allows companies to focus on research and development while outsourcing the production process to specialized manufacturers.
Market Players
- Pfizer Inc.
- Novartis AG
- Biocon
- Amgen Inc.
- Celltrion Inc.
- Samsung Bioepis
- Mylan N.V.
Key players in the global biosimilar market include Pfizer Inc., Novartis AG, Biocon, Amgen Inc., Celltrion Inc., Samsung Bioepis, and Mylan N.V. These companies are actively involved in research and development activities to expand their biosimilar product portfolios and strengthen their market presence. Pfizer Inc. and Novartis AG are among the leading players in the market, leveraging their strong distribution networks and strategic partnerships to enhance their market share. Biocon, a prominent player in the biosimilar space, is focused on developing high-quality biosimilars to address unmet medical needs. Amgen Inc. and Celltrion Inc. are also key players, known for their innovative biosimilar products and commitment to improving patient access to affordable biologic therapies. Samsung Bioepis and Mylan N.V. are emerging players in the market, aiming to capitalize on the growing demand for biosimilars worldwide.
DDDDDThe global biosimilar market is poised for robust growth driven by various factors such as increasing chronic diseases prevalence, rising demand for affordable treatment options, advancements in biotechnology, and favorable government initiatives to promote biosimilar adoption. One of the key trends shaping the market is the shift towards recombinant non-glycosylated proteins, which are gaining traction due to their efficacy and cost-effectiveness. This segment is expected to witness substantial growth as healthcare providers and patients seek alternatives to expensive biologics. Moreover, recombinant glycosylated proteins and peptides are also contributing to the market expansion by addressing unmet medical needs in indications such as oncology, chronic diseases, autoimmune diseases, and infectious diseases.
In terms of indication, oncology remains a dominant segment in the biosimilar market, driven by the increasing burden of cancer globally and the need for more accessible treatment options. Biosimilars offer a promising solution by providing affordable alternatives to biologics, thereby improving patient access to life-saving therapies. Chronic disease and autoimmune disease segments are also growing steadily, supported by advancements in biosimilar development and increasing awareness among healthcare professionals and patients. Additionally, the infectious disease segment is witnessing growth due to the rising demand for effective treatments against infectious pathogens.
When it comes to manufacturing, both in-house and contract manufacturing play crucial roles in the biosimilar market ecosystem. Companies opting for in-house manufacturing have greater control over the production process, quality assurance, and intellectual property rights. On the other hand, contract manufacturing offers flexibility, scalability, and cost-efficiency, allowing companies to focus on core competencies such as research and development. The trend towards contract manufacturing is expected to continue as companies strive to streamline operations and reduce production costs.
Key market players such as Pfizer Inc., Novartis AG, Biocon, Amgen Inc., Celltrion Inc., Samsung Bioepis, and Mylan N.V. are driving innovation and market growth through strategic collaborations, product launches, and investments in research and development. These companies are at the forefront of biosimilar development, leveraging their expertise and resources to bring high-quality, affordable biologic therapies to patients worldwide. As the biosimilar market evolves, market players are likely to focus on expanding their product portfolios, enhancing manufacturing capabilities, and strengthening global distribution networks to capitalize on the growing demand for biosimilars.The global biosimilar market is experiencing significant growth propelled by the increasing prevalence of chronic diseases, the demand for cost-effective treatment options, and advancements in biotechnology. One of the key drivers of market expansion is the shift towards recombinant non-glycosylated proteins, which are gaining prominence for their efficacy and affordability. This trend is expected to continue as healthcare providers and patients seek alternatives to expensive biologics. Additionally, recombinant glycosylated proteins and peptides are also playing a vital role in addressing unmet medical needs across various therapeutic areas, including oncology, chronic diseases, autoimmune diseases, and infectious diseases. The market is witnessing a surge in demand for biosimilars as they offer more accessible and affordable treatment options compared to biologics.
Oncology remains a dominant segment in the biosimilar market, driven by the rising burden of cancer worldwide and the need for innovative and cost-effective therapies. Biosimilars are positioned as a promising solution to improve patient access to life-saving cancer treatments. The chronic disease and autoimmune disease segments are also experiencing steady growth, supported by advancements in biosimilar development and increased awareness among healthcare stakeholders. Furthermore, the infectious disease segment is witnessing traction, fueled by the growing demand for effective treatments against infectious pathogens. The diverse range of indications catered to by biosimilars underscores their potential to address significant healthcare challenges globally.
In terms of manufacturing, both in-house and contract manufacturing are integral to the biosimilar market ecosystem. Companies leveraging in-house manufacturing benefit from greater control over quality assurance and intellectual property rights. In contrast, contract manufacturing offers advantages in terms of flexibility, scalability, and cost-efficiency, enabling companies to focus on core competencies such as research and development. The trend towards contract manufacturing is expected to persist as companies seek to optimize operational efficiency and reduce production costs. This dual approach to manufacturing reflects the dynamic nature of the biosimilar market, where agility and innovation are critical for success.
Key market players such as Pfizer Inc., Novartis AG, Biocon, Amgen Inc., Celltrion Inc., Samsung Bioepis, and Mylan N.V. are driving market growth through strategic collaborations, product launches, and investments in research and development. These industry leaders are at the forefront of biosimilar innovation, working towards expanding their product portfolios, enhancing manufacturing capabilities, and strengthening global distribution networks. As the biosimilar market continues to evolve, market players are expected to focus on addressing unmet medical needs, improving patient access to biologic therapies, and contributing to the advancement of healthcare worldwide.
Access detailed insights into the company’s market position
https://www.databridgemarketresearch.com/reports/global-biosimilar-market/companies
Alternative Research Questions for Global Biosimilar Market Analysis
What is the current valuation of the global Biosimilar Market?
What CAGR is projected for the Biosimilar Market over the forecast period?
What are the key segments analyzed in the Biosimilar Market report?
Which companies dominate the Biosimilar Market landscape?
What geographic data is covered in the Biosimilar Market analysis?
Who are the leading firms operating in the Biosimilar Market?
Browse More Reports:
Saudi Arabia Power Tools Market
Middle East and Africa Travel Beauty Retail Market
Middle East and Africa Sports Betting Market
North America Sports Betting Market
Asia-Pacific Ultraviolet (UV) Curing System Market
Asia-Pacific Gene Therapy Market
Europe Preclinical Imaging Market
India Building Management System Market
Global 5G Service Market
Global Acute Intermittent Porphyria Market
Global Affective Computing Market
Global Allergy Diagnostics Market
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market
Global Ambient Assisted Living and Smart Home Market
Global Angelman Syndrome Treatment Market
About Data Bridge Market Research:
An absolute way to forecast what the future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 975
Email:- corporatesales@databridgemarketresearch.com
"
The global biosimilar market size was valued at USD 64.93 billion in 2024 and is expected to reach USD 598.55 billion by 2032, at a CAGR of 32.00% during the forecast period
The market expansion is primarily driven by the growing number of patent expiries of blockbuster biologics and the rising prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes, which are fueling demand for cost-effective alternatives
In addition, favorable regulatory frameworks, increasing investments from pharmaceutical companies, and greater healthcare provider acceptance are accelerating the development and adoption of biosimilars worldwide. These trends are significantly contributing to the strong growth trajectory of the biosimilar industry
The Biosimilar Market analysis report focuses on leading global industry players, providing information such as company profiles, product pictures and specifications, capacity, production, price, cost, revenue, and contact information. Geographically, this report is categorized into various main regions, including sales, proceeds, market share and expansion rate (percent) in the following areas: North America, Asia-Pacific, South America, Europe, Asia-Pacific, The Middle East and Africa. What is more, the feasibility of new investment projects is assessed and overall research conclusions are offered. Analysis of profiles of manufacturers or commanding players of the global market is performed based on sales area, key products, gross margin, revenue, price, and production.
Biosimilar Market Analysis report analyzes the changing trends in the industry. The industry development trends and marketing channels are also analyzed. In this market document, development policies and plans are discussed, and manufacturing processes and cost structures are also analyzed. The report offers a detailed analysis of Biosimilar Market industry with growth & significant CAGR during the forecast period by top manufacturer’s analysis, region, types, and market segment by applications. The market research study of this report is conducted to understand the current landscape of the global market.
Stay ahead with crucial trends and expert analysis in the latest Biosimilar Market report. Download now:
https://www.databridgemarketresearch.com/reports/global-biosimilar-market
Biosimilar Industry Overview
Segments
- By Product Type
- Recombinant Non-Glycosylated Proteins
- Recombinant Glycosylated Proteins
- Recombinant Peptides
- By Indication
- Oncology
- Chronic Disease
- Autoimmune Disease
- Infectious Disease
- By Manufacturing
- In-House Manufacturing
- Contract Manufacturing
The global biosimilar market is segmented based on product type, indication, and manufacturing. In terms of product type, the market is categorized into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins segment is expected to witness significant growth due to the increasing prevalence of chronic diseases and the demand for cost-effective treatment options. By indication, the market is segmented into oncology, chronic disease, autoimmune disease, and infectious disease. The oncology segment is anticipated to dominate the market as biosimilars offer a more affordable alternative to expensive biologics for cancer treatment. When it comes to manufacturing, the market is divided into in-house manufacturing and contract manufacturing. Contract manufacturing is gaining traction as it allows companies to focus on research and development while outsourcing the production process to specialized manufacturers.
Market Players
- Pfizer Inc.
- Novartis AG
- Biocon
- Amgen Inc.
- Celltrion Inc.
- Samsung Bioepis
- Mylan N.V.
Key players in the global biosimilar market include Pfizer Inc., Novartis AG, Biocon, Amgen Inc., Celltrion Inc., Samsung Bioepis, and Mylan N.V. These companies are actively involved in research and development activities to expand their biosimilar product portfolios and strengthen their market presence. Pfizer Inc. and Novartis AG are among the leading players in the market, leveraging their strong distribution networks and strategic partnerships to enhance their market share. Biocon, a prominent player in the biosimilar space, is focused on developing high-quality biosimilars to address unmet medical needs. Amgen Inc. and Celltrion Inc. are also key players, known for their innovative biosimilar products and commitment to improving patient access to affordable biologic therapies. Samsung Bioepis and Mylan N.V. are emerging players in the market, aiming to capitalize on the growing demand for biosimilars worldwide.
DDDDDThe global biosimilar market is poised for robust growth driven by various factors such as increasing chronic diseases prevalence, rising demand for affordable treatment options, advancements in biotechnology, and favorable government initiatives to promote biosimilar adoption. One of the key trends shaping the market is the shift towards recombinant non-glycosylated proteins, which are gaining traction due to their efficacy and cost-effectiveness. This segment is expected to witness substantial growth as healthcare providers and patients seek alternatives to expensive biologics. Moreover, recombinant glycosylated proteins and peptides are also contributing to the market expansion by addressing unmet medical needs in indications such as oncology, chronic diseases, autoimmune diseases, and infectious diseases.
In terms of indication, oncology remains a dominant segment in the biosimilar market, driven by the increasing burden of cancer globally and the need for more accessible treatment options. Biosimilars offer a promising solution by providing affordable alternatives to biologics, thereby improving patient access to life-saving therapies. Chronic disease and autoimmune disease segments are also growing steadily, supported by advancements in biosimilar development and increasing awareness among healthcare professionals and patients. Additionally, the infectious disease segment is witnessing growth due to the rising demand for effective treatments against infectious pathogens.
When it comes to manufacturing, both in-house and contract manufacturing play crucial roles in the biosimilar market ecosystem. Companies opting for in-house manufacturing have greater control over the production process, quality assurance, and intellectual property rights. On the other hand, contract manufacturing offers flexibility, scalability, and cost-efficiency, allowing companies to focus on core competencies such as research and development. The trend towards contract manufacturing is expected to continue as companies strive to streamline operations and reduce production costs.
Key market players such as Pfizer Inc., Novartis AG, Biocon, Amgen Inc., Celltrion Inc., Samsung Bioepis, and Mylan N.V. are driving innovation and market growth through strategic collaborations, product launches, and investments in research and development. These companies are at the forefront of biosimilar development, leveraging their expertise and resources to bring high-quality, affordable biologic therapies to patients worldwide. As the biosimilar market evolves, market players are likely to focus on expanding their product portfolios, enhancing manufacturing capabilities, and strengthening global distribution networks to capitalize on the growing demand for biosimilars.The global biosimilar market is experiencing significant growth propelled by the increasing prevalence of chronic diseases, the demand for cost-effective treatment options, and advancements in biotechnology. One of the key drivers of market expansion is the shift towards recombinant non-glycosylated proteins, which are gaining prominence for their efficacy and affordability. This trend is expected to continue as healthcare providers and patients seek alternatives to expensive biologics. Additionally, recombinant glycosylated proteins and peptides are also playing a vital role in addressing unmet medical needs across various therapeutic areas, including oncology, chronic diseases, autoimmune diseases, and infectious diseases. The market is witnessing a surge in demand for biosimilars as they offer more accessible and affordable treatment options compared to biologics.
Oncology remains a dominant segment in the biosimilar market, driven by the rising burden of cancer worldwide and the need for innovative and cost-effective therapies. Biosimilars are positioned as a promising solution to improve patient access to life-saving cancer treatments. The chronic disease and autoimmune disease segments are also experiencing steady growth, supported by advancements in biosimilar development and increased awareness among healthcare stakeholders. Furthermore, the infectious disease segment is witnessing traction, fueled by the growing demand for effective treatments against infectious pathogens. The diverse range of indications catered to by biosimilars underscores their potential to address significant healthcare challenges globally.
In terms of manufacturing, both in-house and contract manufacturing are integral to the biosimilar market ecosystem. Companies leveraging in-house manufacturing benefit from greater control over quality assurance and intellectual property rights. In contrast, contract manufacturing offers advantages in terms of flexibility, scalability, and cost-efficiency, enabling companies to focus on core competencies such as research and development. The trend towards contract manufacturing is expected to persist as companies seek to optimize operational efficiency and reduce production costs. This dual approach to manufacturing reflects the dynamic nature of the biosimilar market, where agility and innovation are critical for success.
Key market players such as Pfizer Inc., Novartis AG, Biocon, Amgen Inc., Celltrion Inc., Samsung Bioepis, and Mylan N.V. are driving market growth through strategic collaborations, product launches, and investments in research and development. These industry leaders are at the forefront of biosimilar innovation, working towards expanding their product portfolios, enhancing manufacturing capabilities, and strengthening global distribution networks. As the biosimilar market continues to evolve, market players are expected to focus on addressing unmet medical needs, improving patient access to biologic therapies, and contributing to the advancement of healthcare worldwide.
Access detailed insights into the company’s market position
https://www.databridgemarketresearch.com/reports/global-biosimilar-market/companies
Alternative Research Questions for Global Biosimilar Market Analysis
What is the current valuation of the global Biosimilar Market?
What CAGR is projected for the Biosimilar Market over the forecast period?
What are the key segments analyzed in the Biosimilar Market report?
Which companies dominate the Biosimilar Market landscape?
What geographic data is covered in the Biosimilar Market analysis?
Who are the leading firms operating in the Biosimilar Market?
Browse More Reports:
Saudi Arabia Power Tools Market
Middle East and Africa Travel Beauty Retail Market
Middle East and Africa Sports Betting Market
North America Sports Betting Market
Asia-Pacific Ultraviolet (UV) Curing System Market
Asia-Pacific Gene Therapy Market
Europe Preclinical Imaging Market
India Building Management System Market
Global 5G Service Market
Global Acute Intermittent Porphyria Market
Global Affective Computing Market
Global Allergy Diagnostics Market
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market
Global Ambient Assisted Living and Smart Home Market
Global Angelman Syndrome Treatment Market
About Data Bridge Market Research:
An absolute way to forecast what the future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 975
Email:- corporatesales@databridgemarketresearch.com
"
© 2026 生成AIプロンプト研究所「チャプロAI」 All rights reserved.